Tandem Diabetes Care Receives Analyst Rating Upgrades

The medical device company's insulin delivery systems gain positive reviews from industry analysts.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Tandem Diabetes Care, a San Diego-based medical device company focused on innovative insulin delivery systems, has received several recent rating upgrades and price target changes from research analysts covering the stock. The company's flagship t:slim X2 Insulin Pump, which integrates with continuous glucose monitoring (CGM) sensors and features automated insulin delivery, has been the focus of the positive analyst sentiment.

Why it matters

Tandem Diabetes Care is a leading innovator in the insulin pump market, which is a critical segment of the broader diabetes management industry. Positive analyst sentiment can boost investor confidence and drive increased adoption of the company's products, which could improve outcomes for people living with insulin-dependent diabetes.

The details

According to the report, on February 23, 2026, Lake Street Capital upgraded Tandem Diabetes Care's stock rating from 'hold' to an unspecified higher rating. The company's insulin delivery systems, particularly the t:slim X2 Pump, have received praise from analysts for their advanced features and integration with CGM technology.

  • The rating changes were announced on February 23, 2026.

The players

Tandem Diabetes Care, Inc.

A medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. The company's flagship product is the t:slim X2 Insulin Pump.

Lake Street Capital

A research firm that upgraded Tandem Diabetes Care's stock rating from 'hold' to a higher, unspecified rating on February 23, 2026.

Got photos? Submit your photos here. ›

The takeaway

Tandem Diabetes Care's innovative insulin delivery systems, particularly the t:slim X2 Pump, have gained positive recognition from industry analysts, which could drive increased adoption and improved outcomes for people living with insulin-dependent diabetes.